Table 4.
Predictors estimating PSA response decline ≥ 50%.
| Variables | Univariate | Multivariate | ||
|---|---|---|---|---|
| analysis | analysis | |||
| OR (95% CI) | p-Value | OR (95% CI) | p-Value | |
| Gleason sum score | 0.324 | – | ||
| 6–7 | 1 | |||
| 8–10 | 1.39 (0.72–2.68) | |||
| Age | 0.855 | – | ||
| ≤ 68 | 1 | |||
| >68 | 0.94 (0.50–1.78) | |||
| WHO performance status | 0.041 | 0.177 | ||
| 0 | 1 | |||
| 1, 2 | 0.52 (0.27–0.98) | |||
| Cytoreductive extent | 0.078 | – | ||
| Minor cytoreduction | ||||
| Major cytoreduction | ||||
| Total cytoreduction | ||||
| Number of osseous metastases | 0.014 | – | ||
| <5 | 1 | |||
| ≥5 | 0.44 (0.23–0.85) | |||
| Metastatic burden (CHAARTED) | 0.002 | 0.002 | ||
| Low | 1 | 1 | ||
| High | 0.36 (0.19–0.69) | 0.36 (0.19–0.69) | ||
| Risk classification (LATITUDE) | 0.365 | – | ||
| Low-risk | 1 | |||
| High-risk | 0.75 (0.40–1.41) | |||
| Hormone sensitivity | 0.008 | 0.068 | ||
| CRPC | 1 | |||
| HSPC | 2.56 (1.27–5.26) | |||
HSPC, hormone sensitive prostate cancer; CRPC, Castration-resistant prostate cancer; PSA, Prostate-specific antigen. Bold values represent the p-values that are statistically significance.